The U.S. Food and Drug Administration has told Moderna it needs more time to assess the company's emergency use authorization (EUA) request for its COVID-19 vaccine for kids 12-17.
The U.S. Food and Drug Administration has told Moderna it needs more time to assess the company's emergency use authorization (EUA) request for its COVID-19 vaccine for kids 12-17.
Children have been badly hit during the second wave of the pandemic, with a rise in symptomatic infections and post-COVID complications, such as MIS-C.